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Background. This study was undertaken to determine whether rubella immunity infers measles immunity in pregnant women.
Methods. Stored serum samples were obtained from the Iowa State Hygienic Laboratory for evaluation of rubella and measles
immunities with IgG enzyme-linked immunosorbent assay. Results. Nine hundred serum samples were obtained for testing.
The average age of the women at the time of antepartum serum collection was 28 (range, 14 to 44) years. Measles and rubella
immunity were 88% and 98%, respectively; there was no eﬀect of immunity status by age identiﬁed. Eighty eight percent
of those with rubella immunity were also measles immune. There was no association between paired rubella and measles
immunity identiﬁed, P<. 0001. Discussion. Known rubella immunity did not infer measles immunity in our population.
Thus, we recommend that pregnant women exposed to measles be tested and appropriately treated if they are found to be
nonimmune.
Copyright © 2006 Colleen M. Kennedy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Given a renewed public awareness following a recent measles
outbreak in Iowa, several pregnant women inquired about
their measles immunity [1]. While conﬁrmation of measles
immunity is not routinely performed, determination of
rubella immunity is a routine antenatal test in the United
States. Consequently, we questioned whether a woman with
known rubellaimmunity wouldbelikely tohave measlesim-
munity as well.
A preliminary review of the literature conﬁrmed that
measles immunity following vaccination is reported to be
from 95% (1 dose) to 99% (2 doses), and rubella immu-
nity is reported to be 85% to 90% among adults [2]. While
both vaccines have a high immunogenicity, rubella immu-
nity is shown to be somewhat lower than measles immunity.
Thus, depending upon the paired association for immunity,
rubella immunity could be useful as a predictor for measles
immunity among women with known rubella immune sta-
tus. While correlation of rubella and measles immunity has
been reported, the more rigorous statistical tests to deter-
mine paired association have not.
METHODS
Serum was obtained from the Iowa State Hygienic Labora-
tory from samples collected between January of 2004 and
November of 2004 among women seeking antenatal care in
Iowa and submitted for routine testing (hepatitis B). The
UniversityofIowaInternalReviewBoardapprovedthestudy.
The sample size for the study was estimated based on the
primary outcome measure, agreement between measles and
rubella immunity in a population serum sample. The sam-
ple size was calculated using McNemar’s test (paired data)
with level of signiﬁcance 0.05, power 80%, rubella immunity
85%, and measles immunity 97%, which determined that
867 samples would be required to determine a paired asso-
ciation of immunity status.
Rubella immunity was determined by a commercially
available rubella IgG enzyme-linked immunosorbent assay
(ELISA) (BIO-QUANT, Inc., NY, USA). Likewise, measles
(rubeola) immunity was determined with a commercially
available measles IgG ELISA (BIO-QUANT, Inc.).
Statistical analyses were conducted using the Statistical
Analysis System version 9.0 (SAS, NC, USA) to describe the2 Infectious Diseases in Obstetrics and Gynecology
Table 1: Measles and rubella immunities status.
Measles
Rubella Immune Not immune Indeterminate
Immune 780 62 41
Not immune 10 7 0
rates of measles and rubella immunity. The Kappa statis-
tic was utilized to assess concordance of immunity status.
The paired data for each serum sample was evaluated us-
ing McNemar’s test to evaluate whether or not there was a
pairedassociationbetweenimmunitystatuses.TheWilcoxon
rank-sum test was used for nonparametric comparison of
the age means between immune and nonimmune individ-
uals.
RESULTS
Nine hundred serum samples were obtained and tested for
both measles and rubella immunities. The age of the women
was known for 785 samples, with the average age 28 (range
14to44)years.Demographicdatabeyondagewasunknown.
However, the population of Iowa is primarily non-Hispanic
white.
As noted in Table 1, of the 900 samples tested, 790 were
immune, 69 were nonimmune, and 41 were indeterminate
to measles. Similar testing found that 883 samples were im-
mune, and 17 were nonimmune to rubella (none of the
rubella tests were indeterminate). All of the measles indeter-
minatesampleswerefoundtoberubellaimmune.Immunity
tomeaslesandrubellawasfoundtobe88%and98%,respec-
tively.
Measles immunity status was noted for each rubella
immune and rubella nonimmune sample groups to deter-
mine the association of immunity status. The probability
of measles immunity given that a sample was found to be
rubella immune was 88%. There was no concordance be-
tween immunity statuses, Kappa 0.1353 (95% CI 0.0314,
0.2392). Additionally, McNemar’s test rejected a paired asso-
ciation between measles and rubella immunities, P<. 0001.
Even if all the serum samples found to be indeterminate for
measles immunity were found to be measles immune, nei-
ther concordance nor paired association would have been
conﬁrmed (Kappa 0.1366, McNemar’s P<. 0001). The mean
ageofthosewomenineachrubellagroup(immuneandnon-
immune) was the same (28 years). Thus, there was no appar-
ent eﬀect of immunity status by age identiﬁed.
The measles and rubella immunities prevalence identi-
ﬁed in the population studied was diﬀerent than reported
in the literature (noted previously). Therefore, a posthoc
analysis was performed to determine power for the iden-
tiﬁed measles and rubella immunities prevalence in our
population using McNemar’s exact conditional test, with a
computed power of > 0.999, and 0.0458 level of signiﬁ-
cance.
DISCUSSION
In 2005, the CDC independent panel concluded unani-
mously that rubella was no longer endemic in the United
States [3]. Unfortunately, there is still a signiﬁcant minority
of reproductive age women who are rubella susceptible. The
goal of prenatal testing is to identify women for vaccina-
tioninthepostpartumperiodasthemeasles-mumps-rubella
(MMR) vaccine is contraindicated in pregnancy.
The rubella vaccine was licensed in 1969. Since 1969,
rubella-associated morbidity and mortality and the inci-
dence of congenital rubella syndrome have greatly declined
[2]. The rubella vaccine has been administered as part of the
MMR vaccination since 1978. In 1990, a two-dose schedule
was adopted (age 15 months and again at age 4–6 years).
Following vaccination, measurable antibodies are present in
95% of individuals. Lasting immunity is present in 82% to
90% of those who initially seroconverted using the two-dose
regime [4].
The measles vaccine was licensed in 1963. Since 1963,
therehasbeena99%reductionintheincidenceofmeaslesin
the United States [2]. Unlike rubella, antepartum measles in-
fectionhasnoconsistentpatternoffetalanomalies.However,
there is a known increase in spontaneous abortions, prema-
ture births, and maternal morbidity, including pneumonia
andencephalitis.Passiveimmunizationwithinsixdaysofex-
posure is recommended in pregnant women [2].
We found that rubella immunity did not infer measles
immunity in our study population. While correlation has
been reported by others [5, 6] and was also noted in this
study, correlation does not imply the more rigorous statis-
tical associations of agreement or concordance. The large
number of serum samples positive for both rubella and
measles resulted in the correlation we identiﬁed, as would be
expected in an immunized population.
Strengths of our study include the large sample size, and
prospective data analysis. A limitation of our study was that
the serum samples were obtained from Midwest (primar-
ily Caucasian) pregnant women, which limit generalizabil-
ity. However, our ﬁndings agree with large military stud-
ies where participants included both men and women from
across the United States with varying ethnic background and
race [4, 7, 8].
Measles immunity was found to be 88% and rubella im-
munity 98%. The immunity rates for measles and rubella
may diﬀer within the population we studied compared to
thosepreviouslyreported.Alternatively,theassayformeasles
antibody could be less sensitive than the assay for rubella an-
tibody. This would be consistent with the high number of
measles indeterminate results noted and could be related to
the greater number of nonimmune measles results. Further
Investigation may be undertaken to address this possibility.
In conclusion, rubella immunity did not infer measles
immunity in our population. In measles outbreaks as that in
2004, we would be unable to presume a women’s measles im-
munity based on known rubella immunity. Thus, pregnant
women exposed to measles should be tested and treated if
nonimmune.Colleen M. Kennedy et al 3
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